Pfizer Inc (PFE) 29.73 $PFE
Asia stocks rise on earnings, await US growth data
By YURI KAGEYAMA - AP - 2 hrs 17 mins ago
TOKYO (AP) — Asian stocks rose Wednesday ahead of U.S. economic data and as cheery earnings from major Japanese companies such as Honda Motor Co. countered a lower close on Wall Street.
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
After Yesterday's Decline of 1.23%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 1.23%
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSEFE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pfizer's 2Q profit sinks 79 pct but tops forecasts
By LINDA A. JOHNSON - AP - Tue Jul 29, 12:37PM CDT
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jul 29, 10:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Dow Component Pfizer (PFE) To Go Ex-dividend Tomorrow
at The Street - Tue Jul 29, 10:00AM CDT
Wednesday, July 30, 2014 is the ex-dividend date for Dow component (NYSEFE).
Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 29, 9:38AM CDT
Pfizer's (PFE) second quarter results were better-than-expected despite several headwinds like generic competition and the expiration of a few co-promotion agreements.
Stocks Climb In Early Trade; Herbalife, El Pollo Loco Dive
at Investor's Business Daily - Tue Jul 29, 9:31AM CDT
Stocks stepped out to healthy gains in solid trade early Tuesday, despite a weaker than expected reading on May home-price growth. The Nasdaq grabbed a 0.5% gain. The Dow Jones industrial average tacked on 0.4% and the S&P 500 moved up 0.3%. Volume...
Q3 Estimates Beginning to Slip - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Jul 29, 9:15AM CDT
Lower revisions to the magnitude of Q3 estimates will still be a net positive -- we will see how this trend unfolds.
Stock Market Today: U.S. Stocks Higher as Merck, Pfizer Top Expectations
at The Street - Tue Jul 29, 9:00AM CDT
Major U.S. stock markets open higher on Wall Street Tuesday as investors are greeted by upbeat earnings reports.
Harris & Harris Group Invests in Unique NYC Biotech Accelerator
GlobeNewswire - Tue Jul 29, 7:45AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that it is one of the founding investors in the expansion of Accelerator Corporation, an investment vehicle for emerging biotechnology companies, into New York City. Accelerator is the result of collaboration between a consortium of top-tier venture capital and corporate investors, scientific thought leaders, and executive managers who will identify, finance and manage the development of a select group of early stage biotechnology companies. As part of its participation, Harris & Harris Group Managing Director Misti Ushio, Ph.D., will join the board of Accelerator in New York City.
Stock Market Today: Futures Higher as Aetna, Merck Top Expectations
at The Street - Tue Jul 29, 7:14AM CDT
Stock futures are pointing to a higher open on Wall Street Tuesday as investors are greeted by upbeat earnings reports before the bell.
PFIZER REPORTS SECOND-QUARTER 2014 RESULTS
Business Wire - Tue Jul 29, 6:01AM CDT
--Second-Quarter 2014 Adjusted Diluted EPS(2) of $0.58, Reported Diluted EPS(1) of $0.45
European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Business Wire - Tue Jul 29, 6:00AM CDT
--In the AMPLIFY-EXT trial, Eliquis demonstrated a superior reduction in VTE/all-cause death with no statistical difference in major bleeding events vs. placebo
Asia stocks rise on earnings, await US growth data
By YURI KAGEYAMA - AP - 2 hrs 17 mins ago
TOKYO (AP) — Asian stocks rose Wednesday ahead of U.S. economic data and as cheery earnings from major Japanese companies such as Honda Motor Co. countered a lower close on Wall Street.
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
After Yesterday's Decline of 1.23%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. Pfizer Set to Possibly Rebound After Yesterday's Selloff of 1.23%
Comtex SmarTrend(R) - Tue Jul 29, 3:41PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.69 to a high of $30.49. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $29.78 on volume of 37.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. Pfizer's 2Q profit sinks 79 pct but tops forecasts
By LINDA A. JOHNSON - AP - Tue Jul 29, 12:37PM CDT
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jul 29, 10:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Dow Component Pfizer (PFE) To Go Ex-dividend Tomorrow
at The Street - Tue Jul 29, 10:00AM CDT
Wednesday, July 30, 2014 is the ex-dividend date for Dow component (NYSE
FE). Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 29, 9:38AM CDT
Pfizer's (PFE) second quarter results were better-than-expected despite several headwinds like generic competition and the expiration of a few co-promotion agreements.
Stocks Climb In Early Trade; Herbalife, El Pollo Loco Dive
at Investor's Business Daily - Tue Jul 29, 9:31AM CDT
Stocks stepped out to healthy gains in solid trade early Tuesday, despite a weaker than expected reading on May home-price growth. The Nasdaq grabbed a 0.5% gain. The Dow Jones industrial average tacked on 0.4% and the S&P 500 moved up 0.3%. Volume...
Q3 Estimates Beginning to Slip - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Jul 29, 9:15AM CDT
Lower revisions to the magnitude of Q3 estimates will still be a net positive -- we will see how this trend unfolds.
Stock Market Today: U.S. Stocks Higher as Merck, Pfizer Top Expectations
at The Street - Tue Jul 29, 9:00AM CDT
Major U.S. stock markets open higher on Wall Street Tuesday as investors are greeted by upbeat earnings reports.
Harris & Harris Group Invests in Unique NYC Biotech Accelerator
GlobeNewswire - Tue Jul 29, 7:45AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that it is one of the founding investors in the expansion of Accelerator Corporation, an investment vehicle for emerging biotechnology companies, into New York City. Accelerator is the result of collaboration between a consortium of top-tier venture capital and corporate investors, scientific thought leaders, and executive managers who will identify, finance and manage the development of a select group of early stage biotechnology companies. As part of its participation, Harris & Harris Group Managing Director Misti Ushio, Ph.D., will join the board of Accelerator in New York City.
Stock Market Today: Futures Higher as Aetna, Merck Top Expectations
at The Street - Tue Jul 29, 7:14AM CDT
Stock futures are pointing to a higher open on Wall Street Tuesday as investors are greeted by upbeat earnings reports before the bell.
PFIZER REPORTS SECOND-QUARTER 2014 RESULTS
Business Wire - Tue Jul 29, 6:01AM CDT
--Second-Quarter 2014 Adjusted Diluted EPS(2) of $0.58, Reported Diluted EPS(1) of $0.45
European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Business Wire - Tue Jul 29, 6:00AM CDT
--In the AMPLIFY-EXT trial, Eliquis demonstrated a superior reduction in VTE/all-cause death with no statistical difference in major bleeding events vs. placebo
